Endocare delisted from Nasdaq:
This article was originally published in Clinica
Executive Summary
Urology diagnostic and device firm Endocare has been delisted from the Nasdaq stock market. Trading in the Irvine, California company's shares had been suspended since December 12. It had failed to provide financial reports, and the situation was exacerbated by its auditor admitting a lack of faith in senior management and the sacking of the chief financial officer (see Clinica No 1039, p 8). Endocare plans to appeal the delisting order, but there is no stay on the decision and trading on the OTC Bulletin Board is also banned because the company has not provided required filings to the Securities and Exchange Commission.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.